Poolbeg Pharma (AIM: POLB, OTCQB: POLBF), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announces that it has received notification on
Poolbeg Pharma PLC (AIM:POLB) Board Role Change and Launch of EIP
Board Role Change and Launch of Employee Performance Incentive Plan
Poolbeg Pharma PLC (AIM:POLB) Market Opportunity for POLB 001 for CRS
Independent Research Confirms >$10bn Market Opportunity for POLB 001 as a Preventative Therapy for Cancer Immunotherapy-Induced Cytokine Release Syndrome (CRS)
Poolbeg Pharma PLC (AIM:POLB) Further data shows POLB001 potential in cancer CRS
Further Data Confirms POLB 001’s Potential in Cancer Immunotherapy-Induced Cytokine Release Syndrome (CRS) Market opportunity estimated to be greater than US$1 billion
Poolbeg Pharma PLC (AIM:POLB) RSV AI Drug Candidate Analysis Update
Positive Outputs from Lab-Based Analysis of RSV Drug Candidates Identified Using AI RSV drug candidates with the highest probability of success prioritised
Poolbeg Pharma PLC – POLB 001 Data Presented at ASH
POLB 001 – targeting Cytokine Release Syndrome (CRS) associated with cancer immunotherapies
Poolbeg Pharma PLC (AIM:POLB) Directorate Change
Poolbeg Pharma PLC (AIM: POLB, OTCQB: POLBF) has announced the resignation of Patrick Ashe, an independent director who played a pivotal role in guiding the company through its early stages
Poolbeg Pharma PLC (AIM:POLB) Immunomodulator II patent granted in Japan
Further enhancement of the patent portfolio
Poolbeg Pharma PLC (AIM:POLB) POLB 001 LPS Trial Data to be Presented at IUIS
POLB 001 – a potential blockbuster immunomodulator
Poolbeg Pharma PLC (AIM:POLB) Former Amryt Pharma Leadership Team join Poolbeg
Key Senior Members of Former Amryt Pharma Leadership Team join Poolbeg Pharma Poolbeg team boosted by highly experienced executives with track record of success
Poolbeg Pharma plc (AIM:POLB) POLB 001 Data to be Presented at American Society of Hematology Annual Meeting
Potential to address cancer treatment-related Cytokine Release Syndrome
Poolbeg Pharma PLC (AIM:POLB) POLB 001 Oncology Programme Update Meeting
1 November 2023 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need, announces that it will host a meeting for investors